Medium-chain acyl-CoA dehydrogenase deficiency

Jerry Vockley MD PhD

Neurogenetic Disorders

Updated 09.12.2024
Released 11.11.1996
Expires For CME 09.12.2027

Medium-chain acyl-CoA dehydrogenase deficiency

Author: Jerry Vockley MD PhD

See Contributor Disclosures

Editor: Deepa S Rajan MD

Medium-chain acyl-CoA dehydrogenase deficiency

In This Article

Quick Link

Introduction

Overview

Medium-chain acyl-CoA dehydrogenase deficiency is the most common inborn error of metabolism in the United States Caucasian population. Diagnosed symptomatically, the morbidity and mortality are high, but outcome is significantly improved if patients are identified before the onset of symptoms. It is now included on newborn screening in the United States and in many other developed nations. The author highlights the technologies that have made it possible to diagnose this condition in the newborn period in a cost-effective fashion. As a result, more patients will ultimately find their way into adult medicine and neurology clinics in the coming years.

Key points

	• Medium-chain acyl-CoA dehydrogenase deficiency is now reliably identified in newborn screening in all states in the U.S. and many countries.
	• Treatment during acute illnesses consists of maintaining caloric intake with sugar-containing oral or parenteral fluids.
	• Carnitine is rarely, if ever, needed to treat medium-chain acyl-CoA dehydrogenase deficiency.

Historical note and terminology

Medium-chain acyl-CoA dehydrogenase deficiency is an autosomal recessive inborn error of mitochondrial fatty acid beta-oxidation (16). The disorder was not identified until the early 1980s (54) but is now recognized as the most common of the genetic defects in fatty acid oxidation (05). It is the most frequent inborn error of metabolism in Caucasians, especially those of Western European descent. The medical literature prior to 1980 contains references to patients who either were later proven to have medium-chain acyl-CoA dehydrogenase deficiency or probably had this disorder. The possibility of medium-chain acyl-CoA dehydrogenase deficiency should be considered in this older literature in patients described as having dicarboxylic aciduria, infantile Reye syndrome, and, particularly, either "systemic carnitine deficiency" or "primary carnitine deficiency." For example, four patients originally published as having "primary systemic carnitine deficiency" were later shown to have medium-chain acyl-CoA dehydrogenase deficiency (12). The reason for this confusion is that medium-chain acyl-CoA dehydrogenase deficiency and several other genetic defects in acyl-CoA oxidation are associated with secondary carnitine deficiency. Caution must be taken when reviewing discussions of carnitine deficiency that were published between 1970 and 1982 because they can be outdated and misleading.

Clinical manifestations

Presentation and course

	• Medium-chain acyl-CoA dehydrogenase deficiency can be asymptomatic for many years and present suddenly during periods of metabolic stress.
	• Before the addition of medium-chain acyl-CoA dehydrogenase deficiency to newborn screening, it was a common cause of sudden death in 1- to 3-year-old children.
	• Hypoketotic hypoglycemia with or without hyperammonemia is the main clinical feature of medium-chain acyl-CoA dehydrogenase deficiency.
	• Barring complications of an acute episode of decompensation, patients with medium-chain acyl-CoA dehydrogenase deficiency have a normal life expectancy.
	• Chronic morbidity is due to the sequela of acute episodes of decompensation and not to the primary disease.

Patients with medium-chain acyl-CoA dehydrogenase deficiency present with acute episodes of life-threatening hypoketotic coma that are induced by fasting stress (63; 60; 68). The age at first attack is most often between 6 months and 2 years of age, with a mean of 12 months. Onset, however, has been reported as early as the first few days of life, especially when the baby is breastfeeding, and as late as in a 45-year-old woman who died of hypoglycemia following surgery for colon cancer. Patients are usually asymptomatic and appear normal between attacks. The initial episode of illness occurs without warning, and the presence of an underlying metabolic defect cannot be suspected. Episodes of illness are triggered by prolonged fasts of more than 12 to 16 hours (ie, the time that fatty acids become the predominant metabolic fuel). Attacks can be associated with a longer than usual overnight period of fasting or, more commonly, with poor feeding that accompanies a febrile illness or gastroenteritis. Instances of neonatal onset have occurred in association with attempted breastfeeding that produced excessive duration of fasting in the first days after birth.

Sudden death, possibly due to acute cardiac failure or arrhythmia, can occur (24). The life-threatening nature of the illness is emphasized by the fact that before newborn screening, 20% to 25% of patients with medium-chain acyl-CoA dehydrogenase deficiency die during their first attack of illness (18). Physical examination can reveal mild enlargement of the liver, or hepatomegaly can develop during the first 24 hours of treatment as fat is deposited in the liver. Laboratory studies typically reveal hypoglycemia, inappropriately low urinary and plasma ketones, and abnormal liver function tests. It must be emphasized that the toxic effects of fatty acids or other factors probably contribute to the illness because patients can become ill before they develop frank hypoglycemia. Urinary ketones are usually "trace" or less but can be as high as "moderate." Blood ammonium levels in the range of 150 to 200 µmol/L are common, and serum uric acid and urea concentrations are also increased, perhaps reflecting increased protein catabolism. Serum AST and ALT levels are commonly elevated 5 to 10 times normal or greater, and prothrombin and partial thromboplastin times can be prolonged, but serum bilirubin is usually normal. Muscle involvement at times of acute illness is not usually apparent; however, creatine phosphokinase levels up to 12,000 U/L have been reported (51). Liver biopsy at times of illness reveals increased triglyceride accumulation, which can have both a microvesicular and a macrovesicular pattern, but mitochondrial morphology is relatively normal. Pulmonary hemorrhage and cardiac arrest without hypoglycemia have been reported (32).

Once treatment with intravenous glucose is started, most patients recover fully within a few days (47). Irreversible cerebral edema leading to death or permanent brain damage can occur (18). Patients who survive an acute episode of illness can have significant neurologic sequelae, including cerebral palsy, seizures, and developmental disabilities; however, those diagnosed presymptomatically almost always remain without significant clinical problems (69; Wilken 2010; 05).

Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency has significantly altered the clinical picture of this disorder in many countries. Screening is accomplished by examination of the acylcarnitine profile by tandem mass spectroscopy in blood samples from blood spots taken for more traditional newborn screening (43). Except on rare occasions, a definitive and cost-effective diagnosis can now be made before the onset of symptoms. Once identified, affected individuals have fewer episodes of metabolic decompensation and a reduced risk of death (69; 05). Cord blood has been shown to be of limited value for screening newborns (65). Pre-term infants can rarely present with a false-positive newborn screen (34).

Prognosis and complications

As long as excessive periods of fasting are avoided, it is possible for medium-chain acyl-CoA dehydrogenase deficiency to be well tolerated with little or no impact on health or long-term survival (47; 68; 05). Because fasting tolerance improves with age, the risk of episodes of coma decreases in later childhood and adult life. However, fasting can still provoke illness in older patients. Chronic effects on cardiac muscle, such as cardiomyopathy, or skeletal muscle, such as weakness or reduced exercise tolerance, have not been observed, although these are common in other fatty acid oxidation disorders. A prolonged QTc interval has been reported in a 3-day-old infant (72). Recurrent rhabdomyolysis has been reported (45), as have episodes of encephalopathy, emesis, and acute liver failure (48). Several investigators have noted that the number of known patients with medium-chain acyl-CoA dehydrogenase deficiency is considerably lower than would be predicted from the frequency of the mutation. This might reflect a failure to diagnose the disorder in many symptomatic patients. However, it is also possible that a significant number of patients never become symptomatic because they happen to escape ever being exposed to a sufficiently prolonged period of fasting stress.

Even though the medium-chain acyl-CoA dehydrogenase defect can be essentially silent, there is a high frequency of morbidity and mortality due to episodes of fasting coma if the disease remains undiagnosed (18; 70). Without presymptomatic diagnosis (including newborn screening), 20% to 25% of patients can die during their first attack of coma, before the diagnosis of medium-chain acyl-CoA dehydrogenase deficiency has been made, emphasizing the need for early detection by newborn screening. As many as 40% of patients who have survived episodes of coma suffer from chronic neurologic disabilities ranging from mild developmental delay to seizures and cerebral palsy. Sudden death has been reported even in infants identified through newborn screening, so vigilance in the face of this disorder remains appropriate (35).

Clinical vignette

A 19-month-old, previously well girl developed vomiting at bedtime and awoke twice more during the night with dry heaves. Later that night, the family heard an unusual cry from the room and found the child unresponsive on the floor with jerking movements of all extremities. An ambulance was called, and emergency medicine personnel arrived to find the child having a grand mal seizure. Vital signs were stable, and the child was afebrile. Normal saline followed by diazepam was administered intravenously, and the seizure stopped, but by the time the ambulance arrived in the emergency room, the patient had begun seizing again. The physical exam showed a temperature of 98.2°F, pulse of 118, respiration rate of 32, blood pressure of 92/50, and oxygen saturation of 99% on room air by pulse oximetry. The exam was remarkable only for altered mental status with minimal response to pain and low tone. Dextrostix in the emergency room was read as <30, prompting immediate administration of IV 10% glucose at maximum rate. A repeat Dextrostix reading was 70, and the measured glucose level was 75 mg/dl (normal 70 to 120). Serum electrolytes measured simultaneously showed a sodium level of 143 meq/L, potassium 4.8 meq/L, chloride 108 meq/L, and bicarbonate of 18 meq/L (all within the lab’s normal range). The patient remained lethargic and was admitted to the intensive care unit. There, the plasma ammonium level was 350 µmol/L (normal < 35), the lactate was 2.8 µmol/L (normal < 2), and the liver function tests were normal. A head CT was normal with no signs of increased intracranial pressure, and a lumbar puncture showed normal CSF glucose and protein levels with no cells observed. Over the next 6 hours, the patient gradually regained consciousness. A repeat blood ammonium level was 85 mmol/L. The next morning, the patient was described by her parents as being back to normal, and she was discharged to home with instructions to feed frequently. The acylcarnitine profile of blood taken during the initial presentation was notable for elevations of C6-10 saturated and C10:1 unsaturated species. Urine organic acids showed elevations of hexanoylglycine, suberylglycine, octanoate, and C6-10 dicarboxylic acids. A diagnosis of medium-chain acyl-CoA dehydrogenase deficiency was made, and molecular testing confirmed the presence of two copies of the c.985 A>G mutation in the medium-chain acyl-CoA dehydrogenase (ACADM) gene.

Biological basis

	• A common c.985 A>G mutation accounts for most variants in European populations.
	• Medium-chain acyl-CoA dehydrogenase is a mitochondrial enzyme active in the metabolic pathway of fatty acid oxidation.

Etiology and pathogenesis

The basis for the intermittent nature of illness in medium-chain acyl-CoA dehydrogenase deficiency relates to the impairment in the later stages of fasting adaptation when fatty acid oxidation normally increases from less than 10% to greater than 80% of total oxygen consumption. The switch to fatty acid oxidation and ketogenesis begins after 12 to 20 hours of fasting in infants and young children and somewhat later in older children and adults. Fasting studies in medium-chain acyl-CoA dehydrogenase deficiency and other defects in fatty acid oxidation illustrate their pathophysiology (60). During fasting in these patients, the plasma levels of free fatty acids begin to rise due to the acceleration of adipose tissue lipolysis at a normal time. However, synthesis of ketones from fatty acids by the liver is impaired and plasma levels of ketones fail to rise appropriately. The inability to utilize fat and to produce ketones as an alternative fuel for the brain results in excessive reliance on glucose as a metabolic fuel and the development of hypoglycemia by 16 to 20 hours of fasting. At the point of hypoglycemia, plasma-free fatty acid concentrations can reach 3 to 4 mmol/L, whereas concentrations of beta-hydroxybutyrate, the major ketone, usually remain below 1 mmol/L. Typical values in normal fasted children are approximately 2 mmol/L for free fatty acids and 3 mmol/L for beta-hydroxybutyrate.

Patients with medium-chain acyl-CoA dehydrogenase deficiency can develop symptoms of lethargy, nausea, and vomiting a few hours before frank hypoglycemia occurs. This appears to correlate with the time when plasma-free fatty acid levels become elevated, suggesting that some of the illness in medium-chain acyl-CoA dehydrogenase deficiency can reflect toxic effects of excessive free fatty acids or their metabolites (63). Hyperammonemia, when present, appears to be related to depletion of intracellular acetyl-CoA and reduced production of N-acetylglutamate. This, in turn, leads to a secondary reduction in the urea cycle (56). The neurologic manifestations can also be enhanced by direct inhibition of neuronal respiratory chain function by the metabolites that accumulate in medium-chain acyl-CoA dehydrogenase deficiency (40) or by loss of critical functions related to specific acylcarnitines (21).

Mitochondrial fatty acid oxidation is predominantly responsible for the oxidation of fatty acids of carbon length 20 or less, whereas the peroxisomal pathway is physiologically more relevant for longer-chain fatty acids (60). Mitochondrial beta-oxidation is a complex process involving the transport of activated acyl-CoA moieties into the mitochondria and sequential removal of two carbon acetyl-CoA units. The pathway of mitochondrial fatty acid oxidation is initiated by the activation of free fatty acids to acyl-CoA esters in the cytosol. The fatty acids are then transferred across the mitochondrial membrane bound to carnitine. Within the mitochondrial matrix, the fatty acids are converted back to acyl-CoA. The four steps of the beta-oxidation cycle then sequentially remove two carbons until the acyl-CoA (n carbons) is fully converted to n/2 acetyl-CoA molecules. In peripheral tissues, the acetyl-CoA is terminally oxidized in the Krebs cycle for ATP production. In the liver, the acetyl-CoA from fatty acid oxidation is used via the beta-hydroxy-beta-methylglutaryl-CoA pathway for the synthesis of ketones, beta-hydroxybutyrate, and acetoacetate, which are then exported for final oxidation by brain and other tissues.

Beta-oxidation of the mitochondrial matrix

The altered bonds in each reaction are shown in red. Medium-chain acyl-CoA dehydrogenase deficiency works at the acyl-CoA dehydrogenase step with maximum activity for octanoyl-CoA as substrate. (Contributed by Dr. Jerry Vockley.)

At least 25 enzymes and specific transport proteins are responsible for carrying out the steps of mitochondrial fatty acid metabolism (60). Medium-chain acyl-CoA dehydrogenase is one of four chain-length specific enzymes that catalyze the first step of the intramitochondrial beta-oxidation cycle. The acyl-CoA dehydrogenase step in beta-oxidation dehydrogenates fatty acyl-CoA substrates, leading to the insertion of a double bond at the beta-carbon to form an enoyl-CoA. The enoyl-CoA is further processed by three other steps of the beta-oxidation cycle to form acetyl-CoA and an acyl-CoA that is two carbons shorter and can enter another beta-oxidation cycle. The acyl-CoA dehydrogenase reaction also yields one electron, which is transferred via electron transfer flavoprotein to the electron transport chain for ATP production. The medium-chain acyl-CoA dehydrogenase enzyme shows specificity for fatty acyl-CoA's containing 6 to 10 carbons. Because longer-chain fatty acids must pass through the medium-chain acyl-CoA dehydrogenase step for complete oxidation, deficiency of medium-chain acyl-CoA dehydrogenase blocks the utilization of the typical 16- to 18-carbon long-chain fatty acids that make up the majority of endogenous fat stores. Fatty acid oxidation is now recognized as functionally and physically interacting with the mitochondrial respiratory chain in a macromolecular complex (67). Primary defects in medium-chain acyl-CoA dehydrogenase have been shown to disrupt this interaction in patient fibroblasts, with the presence of secondary defects in oxidative phosphorylation (30). The clinical relevance of this finding is unclear, as patients do not exhibit any overt signs of respiratory chain deficiency.

Medium-chain acyl-CoA dehydrogenase is synthesized in a larger precursor form in the cytoplasm from nuclear-encoded transcripts and then transported into mitochondria (19). Once inside the mitochondrial matrix, the leader peptide is removed by a specific protease, and the mature subunits assemble into the active homotetramer. One molecule of FAD is noncovalently attached to each medium-chain acyl-CoA dehydrogenase subunit. cDNAs for each of these proteins have been cloned, and sequence analysis shows that they are approximately 30% to 35% conserved, suggesting evolution from a common primordial gene (57). Active enzyme is a homotetramer containing 1 mole of riboflavin/subunit.

The vast majority of patients with medium-chain acyl-CoA dehydrogenase deficiency have a single common missense mutation: an A-to-G transition at cDNA position 985, which changes a lysine residue to glutamate at amino acid 329 of the medium-chain acyl-CoA dehydrogenase precursor protein (58; 02). The mutated amino acid is far removed from the catalytic site of the enzyme but appears to make the protein unstable by interfering with intramitochondrial folding and assembly of the nascent peptide (33). Preventing this misfolding offers an opportunity to develop therapeutic agents for medium-chain acyl-CoA dehydrogenase deficiency (14; 26).

The ACADM c.985 A>G pathogenic variant accounts for approximately 90% of the mutant alleles in medium-chain acyl-CoA dehydrogenase deficiency. Approximately 70% of patients are homozygous for the c.985 A>G variant (58; 02). Most of the remaining patients are compound heterozygotes for the c.985 A>G allele in combination with one of several rarer mutations. Thus, only a few percent of medium-chain acyl-CoA dehydrogenase patients do not have at least one c.985 A>G allele. The unusually high frequency of a single common mutation has made molecular diagnosis especially valuable in medium-chain acyl-CoA dehydrogenase deficiency. As more information accumulates from patients identified through newborn screening, correlation of phenotype with genotype is becoming clearer. Patients with the common mutation accumulate the highest levels of metabolites in the newborn period and are probably at risk for more severe disease than are patients with many other mutations (06; 64). However, genotype-phenotype correlations are not consistent (03). In babies identified by newborn screening in New York State, outcomes were correlated to levels of octanoylcarnitine in the screening blood spot, which, in turn, was less tightly correlated to genotype (03). Analysis of urine acylglycine levels can provide additional insight into the risk for symptoms in infants identified through newborn screening, with elevated hexanoylglycine correlated to more severe phenotype (49). Of note, it has been shown that the elevated levels of acylcarnitines in patients with medium-chain acyl-CoA dehydrogenase deficiency correlate to levels of acyl-ghrelin, highlighting the potential for unexpected secondary effects remote from the primary defect (01).

Differential diagnosis

	• Fasting and stress-induced hypoglycemia mimics other fatty acid oxidation disorders.
	• Consider medium-chain acyl-CoA dehydrogenase deficiency in the context of “recurrent Reye syndrome.”

Confusing conditions

The presentation of acute life-threatening coma in medium-chain acyl-CoA dehydrogenase deficiency can resemble a wide range of acquired and congenital disorders. This presentation is typical of most of the dozen known genetic defects in the fatty acid oxidation pathway, and specific testing is required to differentiate among these disorders: plasma membrane carnitine transporter defect, carnitine palmitoyltransferase I deficiency, carnitine and acylcarnitine translocase deficiency, carnitine palmitoyltransferase II deficiency, very long-chain acyl-CoA dehydrogenase deficiency, long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, short-chain acyl-CoA dehydrogenase deficiency, HMG synthase deficiency, HMG lyase deficiency, electron transfer flavoprotein deficiency, and electron transfer flavoprotein dehydrogenase deficiency (63). The clinical features mimic those originally described as Reye syndrome, and indeed, most such cases are now found to be due to an inborn error of metabolism. The hypoglycemia found in medium-chain acyl-CoA dehydrogenase deficiency is also seen in a wide range of disorders. The relatively long period of fasting required to induce illness, the mild degree of acidemia, and modest hepatomegaly help to distinguish medium-chain acyl-CoA dehydrogenase deficiency from glycogen storage disorders and gluconeogenic defects. The duration of prior fasting and age of onset are similar to ketotic hypoglycemia of infancy and hypopituitarism, and specific tests can be necessary to distinguish these from medium-chain acyl-CoA dehydrogenase deficiency. Hypoglycemia and coma can accompany genetic defects in amino acid oxidation, such as isovaleric acidemia (61). These are usually associated with more severe acidemia than medium-chain acyl-CoA dehydrogenase deficiency and can be distinguished by their distinctive abnormalities on urine organic acid profiles. The hyperammonemia seen with acute illness in medium-chain acyl-CoA dehydrogenase deficiency can suggest a urea cycle disorder, but the elevation of blood ammonia is usually milder, and attacks of illness in the urea cycle defects are often provoked by protein feeding rather than prolonged fasting. Similar degrees of hyperammonemia with hypoketotic hypoglycemia also occur in patients with hyperinsulinism due to mutations of glutamate dehydrogenase (hyperinsulinism and hyperammonemia syndrome) (55). Hypoketotic hypoglycemia can be induced by ingestion of oral hypoglycemic drugs or surreptitious insulin administration. Jamaican vomiting illness is a Reye-like illness induced by hypoglycin A, a toxic amino acid present in unripe Akee fruit, which inhibits medium-chain acyl-CoA dehydrogenase and other acyl-CoA dehydrogenase enzymes (59).

Diagnostic workup

	• Medium-chain acyl-CoA dehydrogenase deficiency is identified by newborn screening in many developed countries.
	• Symptomatic diagnosis requires the collection of samples during an acute episode as metabolic testing can normalize when a patient is well.

During an acute attack of medium-chain acyl-CoA dehydrogenase deficiency, the critical blood and urine samples, obtained immediately as treatment is begun, are most useful in making the diagnosis (42; 04; 62). As indicators of the presence of a defect in fatty acid oxidation, these critical samples can show hypoglycemia; minimal acidemia; elevated blood urea nitrogen, ammonium, uric acid, and liver transaminases; abnormal coagulation tests; possible elevation of creatine phosphokinase; and, especially, inappropriately low urine ketones. The demonstration of elevated levels of free fatty acid and low beta-hydroxybutyrate concentrations in plasma is especially helpful in establishing that ketogenesis is impaired. These same markers are useful in following the clinical course in known patients. Portions of the critical plasma and urine samples should be preserved for some of the tests described below that can specifically diagnose medium-chain acyl-CoA dehydrogenase deficiency because abnormalities are often most apparent during fasting stress.

Measurement of plasma-free and total carnitine in the nonfasted state provides a useful clue to the presence of an underlying defect in acyl-CoA oxidation, such as medium-chain acyl-CoA dehydrogenase deficiency. These disorders are commonly associated with secondary carnitine deficiency with total carnitine levels 25% to 50% of normal and reduction in percent free carnitine below the values of 80% to 90% seen in well-fed normal individuals (42). The test is less useful during times of illness, when total carnitine levels can rise acutely to normal or greater than normal values. The pattern of secondary carnitine deficiency can also occur in other acyl-CoA oxidation defects involving fatty acid oxidation (deficiencies of carnitine and acylcarnitine translocase deficiency, carnitine palmitoyltransferase II, long-chain and very long-chain acyl-CoA dehydrogenase, long-chain 3-hydroxyacyl-CoA dehydrogenase, short-chain acyl-CoA dehydrogenase, electron transfer flavoprotein, electron transfer flavoprotein dehydrogenase, or HMG-CoA lyase) or organic acid oxidation (isovaleric acidemia, methylmalonic aciduria, propionic acidemia).

Several special methods for the specific diagnosis of medium-chain acyl-CoA dehydrogenase deficiency based on metabolite analysis are available. For plasma, these include assay of the acylcarnitine profile by tandem mass spectrometry (octanoylcarnitine, decenoylcarnitine) and of the fatty acid profile by gas chromatography and mass spectrometry (octanoate, cis-dec-4-enoate) (10; 42). Care must be taken to avoid mischaracterization of other medium-chain acyl-CoA dehydrogenase deficiency-related metabolites as glutarylcarnitine because the presence of this compound would suggest instead a diagnosis of glutaric aciduria (37). Both of these methods can also be used with newborn blood spot cards, eg, for postmortem retrospective diagnosis or for neonatal screening. Tandem mass spectrometry can detect abnormal acylcarnitine profiles in various metabolic defects, including medium-chain acyl-CoA dehydrogenase deficiency. The ratio of C8/C8:1 carnitine species appears to be more specific for disease than the C8 level alone (17). For urine, specific diagnostic tests include assay of the organic acid profile by gas chromatography and mass spectrometry, especially if quantitated using isotope dilution methods (hexanoylglycine, phenylpropionylglycine, suberylglycine) (41). The organic acid profile of the critical urine specimen will also show elevations of medium-chain dicarboxylic acids (adipic, suberic, sebacic) out of proportion for the levels of ketones (42). This is a nonspecific finding of impaired fatty acid oxidation that is common to all of the fatty acid oxidation disorders. Diagnosis can also be made postmortem on tissue extracts (08).

The diagnosis of medium-chain acyl-CoA dehydrogenase deficiency can be conveniently established in many instances using molecular techniques to identify the common c.985 A>G mutation (58; 02). Molecular diagnosis can be done on genomic DNA specimens from peripheral blood samples, Guthrie card blood spots, cultured fibroblasts or lymphoblasts, as well as postmortem tissue samples. Molecular diagnosis is highly likely to be successful in medium-chain acyl-CoA dehydrogenase deficiency because 70% of patients are homozygous for the common c.985 A>G mutation.

Diagnosis by demonstration of deficient medium-chain acyl-CoA dehydrogenase enzyme activity can be carried out using cultured fibroblasts or lymphoblasts and freshly isolated leukocytes but is not necessary if molecular confirmation is definitive (13). With the development of highly specific metabolite tests and molecular diagnosis methods, direct assay of enzyme activity is rarely necessary. Cultured fibroblasts and lymphoblasts can be used to test the integrity of the fatty acid oxidation pathway using radio-labeled or stable isotope-labeled fatty acid substrates (25; 36).

The diagnosis of a beta-oxidation defect, including medium-chain acyl-CoA dehydrogenase deficiency, should be considered in anyone who dies suddenly and unexpectedly or has an acute life-threatening event, especially suspected sudden infant death syndrome. This includes collecting and storing blood and urine samples at the time of presentation and harvesting of liver, muscle, and bile as rapidly as possible after death with rapid freezing of all samples without fixation (44). A fibroblast tissue culture should be established for later analysis. This maximizes the chance that a specific diagnosis can be made postmortem.

Management

	• The provision of calories, intravenously if necessary, during times of illness is key to preventing or limiting the extent of metabolic decompensation.
	• Carnitine supplementation is usually not necessary for patients with medium-chain acyl-CoA dehydrogenase deficiency.
	• Avoid the administration of supplements and formula containing medium-chain triglyceride oil.
	• Intellectual outcome is normal in patients with medium-chain acyl-CoA dehydrogenase deficiency barring neurologic damage due to metabolic decompensation.

Treatment of acute episodes of coma in medium-chain acyl-CoA dehydrogenase deficiency is primarily supportive and aimed at quickly reversing the catabolic state that is responsible for stimulating the pathways of lipolysis and fatty acid oxidation (04; 62). Hypoglycemia should be corrected with bolus administration of intravenous dextrose. Continuous infusion of dextrose should then be given at a rate that maintains plasma glucose levels at, or slightly above, the normal range to stimulate insulin secretion and suppress adipose tissue lipolysis. This usually requires 10% dextrose solutions at maintenance rates or higher if dehydration exists. Specific therapy for the mild hyperammonemia that can be present during acute illness has not usually been required. Cerebral edema has occurred during treatment in some patients with severe coma, possibly as a late reflection of acute brain injury from hypoglycemia, toxic effects of fatty acids, or ischemia. Recovery from the acute metabolic derangements associated with coma can require more than a few hours but is usually complete within 12 to 24 hours except where serious injury to the brain has occurred.

Long-term management consists of dietary therapy to prevent excessive periods of fasting that can lead to coma. However, there is considerable variation across metabolic centers (38). Overnight fasting should be limited to no more than 10 to 12 hours by providing a high-carbohydrate snack at bedtime and ensuring that breakfast is not skipped or delayed (20). More frequent feedings of carbohydrates should be offered during times of intercurrent illness because appetite can be reduced. Episodes of gastroenteritis are especially dangerous, and early intervention with intravenous dextrose is advisable to prevent coma from developing. Home blood glucose monitoring is not useful because symptomatic illness can begin before hypoglycemia has occurred. Although it is reasonable to modestly reduce dietary fat because this fuel cannot be used efficiently in medium-chain acyl-CoA dehydrogenase deficiency, patients appear to tolerate normal diets without difficulty, and severe restriction of fat intake can be unnecessary. However, changes observed in the plasma lipidome of children with non-decompensated MCADD suggest an underlying alteration in lipid metabolism, and longitudinal monitoring and further in-depth investigations have been suggested to better understand the long-term impacts of these changes (15).

Formulas containing medium-chain triglyceride oil should be avoided. Special attention should be paid to premature infants who can have started on such formulas before the return of a newborn screening result.

Although patients with medium-chain acyl-CoA dehydrogenase deficiency and other acyl-CoA oxidation defects have secondary carnitine deficiency, the use of carnitine supplementation in these disorders is controversial (50). The mechanism of carnitine deficiency appears to be reduced transport of free carnitine in the kidney and other tissues (12; 53), possibly secondary to inhibition of the plasma membrane carnitine transporter by increased levels of medium and long-chain acylcarnitines (53). It has been speculated that carnitine might help to remove potentially toxic acyl-CoA intermediates and serve either as an adjunct to treatment of acute illness or to prevent attacks of coma. However, the amounts of abnormal acylcarnitines excreted in the urine are rather modest, even with carnitine supplementation, and there is no clear evidence that carnitine is beneficial either during acute crises or in long-term management (52). Some investigators suggest 50 to 100 mg/day of oral carnitine. The present authors do not recommend using carnitine in medium-chain acyl-CoA dehydrogenase-deficient patients except for investigational purposes. The use of bezafibrate to induce fatty acid oxidation enzymes has been proposed as a therapy for long-chain fatty acid oxidation defects (09). Success appears to depend on the presence of partially stable but enzymatically impaired protein. A similar approach can be useful in medium-chain acyl-CoA dehydrogenase deficiency in some circumstances, but it has not yet been tested (29).

Fibroblasts from patients with MCAD deficiency have been shown to metabolize heptanoic acid as substrate, suggesting that triheptanoin (a medication approved for treatment of long-chain fatty acid oxidation) could be effective in MCAD deficiency (22). This result is surprising as octanoate is toxic in this disorder. The disparity is due to the ability of short-chain acyl-CoA dehydrogenase to utilize heptanoyl-CoA and not octanoyl-CoA as substrate. The same publication identified several other medium-branched-chain substrates that might also be therapeutic.

Outcomes

Apart from the risk of episodes of illness with excessive fasting stress, the medium-chain acyl-CoA dehydrogenase defect is essentially silent. Patients appear to be normal and have no noticeable impairment in skeletal or cardiac muscle function. Sudden death due to metabolic decompensation can still occur if appropriate treatment is not obtained during illnesses. Thorough investigations of family members of patients with medium-chain acyl-CoA dehydrogenase deficiency are important as several instances of affected individuals who have never become symptomatic, even into adult life, have been recognized (18; 07; 27). Because fasting tolerance normally increases with age, the risk of illness due to medium-chain acyl-CoA dehydrogenase deficiency decreases in older children and adults. One case report has emphasized the need to consider medium-chain acyl-CoA dehydrogenase deficiency in patients with mental status changes suspected of drug toxicity (39).

Special considerations

Pregnancy

Issues that need to be considered with pregnancy in medium-chain acyl-CoA dehydrogenase deficiency include the health of an affected mother, prenatal diagnosis of an affected fetus, and management of an affected newborn. Minimal experience has been reported formally, but the author has personal experience with successful uneventful pregnancies in affected women and knows of similar experiences at numerous metabolic clinics worldwide. It can be anticipated that pregnancy in a mother affected with medium-chain acyl-CoA dehydrogenase deficiency might be associated with increased risk of coma both because of morning sickness and because of the usual decrease in fasting tolerance during later stages of pregnancy. One woman who was subsequently shown to have medium-chain acyl-CoA dehydrogenase deficiency has been reported to develop fatty liver during pregnancy at 39 weeks gestation (46). Extra care should be taken for the affected mother to avoid fasting stress of more than 10 to 12 hours by providing extra carbohydrate feeds. During labor and delivery, intravenous dextrose should be given to maintain high normal levels of plasma glucose and ensure that lipolysis and fatty acid oxidation are suppressed.

With the availability of molecular and other diagnostic techniques, prenatal testing for medium-chain acyl-CoA dehydrogenase deficiency is feasible, although it is likely unnecessary in view of the good prognosis for affected patients. In addition, routine early feeding practices in most nurseries will usually be sufficient to prevent a period of fasting that would induce coma in the newborn period. Nevertheless, as noted above, several case reports have made it clear that newborn infants with medium-chain acyl-CoA dehydrogenase deficiency can develop coma in the neonatal period if excessively fasted. In these reports, coma occurred during the first days after birth in association with attempted breastfeeding. This can be explained by the fact that milk production is often poor during this time. Breastfeeding for the affected newborn should be possible as long as care is taken to provide supplemental feedings until milk production is well established.

Anesthesia

Patients with medium-chain acyl-CoA dehydrogenase deficiency have undergone routine anesthesia and surgery without difficulty though this is rarely reported (66). Precautions should be taken to ensure that preoperative fasting does not exceed 8 hours and that intravenous dextrose infusions are started beyond this time limit in order to prevent activation of fatty acid oxidation. Drugs that stimulate lipolysis and fatty acid oxidation, such as epinephrine and other beta-agonists, theoretically might pose a hazard for patients with medium-chain acyl-CoA dehydrogenase deficiency and other fatty acid oxidation disorders. If these agents are unavoidable, the simultaneous administration of dextrose to minimize fatty acid utilization might be considered.

References

01: Akamizu T, Sakura N, Shigematsu Y, et al. Analysis of plasma ghrelin in patients with medium-chain acyl-CoA dehydrogenase deficiency and glutaric aciduria type II. Eur J Endocrinol 2012;166(2):235-40. PMID 22048973
02: Andresen BS, Dobrowolski SF, O’Reilly L, et al. Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet 2001;68(6):1408-18. PMID 11349232
03: Arnold GL, Saavedra-Matiz CA, Galvin-Parton PA, et al. Lack of genotype-phenotype correlations and outcome in MCAD deficiency diagnosed by newborn screening in New York State. Mol Genet Metab 2010;99(3):263-8. PMID 20036593
04: Bennett MJ, Rinaldo P, Strauss A. Inborn errors of mitochondrial fatty acid oxidation. Crit Rev Clin Lab Sci 2000;37:1-44. PMID 10737439
05: Bentler K, Zhai S, Elsbecker SA, et al. 221 newborn-screened neonates with medium-chain acyl-coenzyme A dehydrogenase deficiency: findings from the inborn errors of metabolism collaborative. Mol Genet Metab 2016;119(1-2):75-82. PMID 27477829
06: Blois B, Riddell C, Dooley K, Dyack S. Newborns with C8-acylcarnitine level over the 90th centile have an increased frequency of the common MCAD 985A>G mutation. J Inherit Metab Dis 2005;28(4):551-6. PMID 15902558
07: Bodman M, Smith D, Nyhan WL, Naviaux RK. Medium-chain acyl coenzyme A dehydrogenase deficiency: occurrence in an infant and his father. Arch Neurol 2001;58(5):811-4. PMID 11346377
08: Boles RG, Martin SK, Blitzer MG, Rinaldo P. Biochemical diagnosis of fatty acid oxidation disorders by metabolite analysis of postmortem liver. Hum Pathol 1994;25(8):735-41. PMID 8056418
09: Bonnefont JP, Bastin J, Behin A, Djouadi F. Bezafibrate for an inborn mitochondrial beta-oxidation defect. N Engl J Med 2009;360(8):838-40. PMID 19228633
10: Chace DH, Hillman SL, Van Hove JL, Naylor EW. Rapid diagnosis of MCAD deficiency: quantitatively analysis of octanoylcarnitine and other acylcarnitines in newborn blood spots by tandem mass spectrometry. Clin Chem 1997;43(11):2106-13. PMID 9365395
11: Derks TG, van Spronsen FJ, Rake JP, van der Hilst CS, Span MM, Smit GP. Safe and unsafe duration of fasting for children with MCAD deficiency. Eur J Pediatr 2007;166(1):5-11. PMID 16788829
12: Engel AG, Rebouche CJ, Wilson DM, Glasgow AM, Romshe CA, Cruse RP. Primary systemic carnitine deficiency. II. Renal handling of carnitine. Neurology 1981;31(7):819-25. PMID 7195503
13: Frerman FE, Goodman SI. Fluorometric assay of acyl-CoA dehydrogenases in normal and mutant human fibroblasts. Biochem Med 1985;33(1):38-44. PMID 3994700
14: Gregersen N, Olsen RK. Disease mechanisms and protein structures in fatty acid oxidation defects. J Inherit Metab Dis 2010;33(5):547-53. PMID 20151199
15: Guerra IM, Ferreira HB, Mauricio T, et al. Plasma lipidomics analysis reveals altered profile of triglycerides and phospholipids in children with medium-chain acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis 2024;47(4):731-45. PMID 38356271
16: Hale DE, Bennett MJ. Fatty acid oxidation disorders: a new class of metabolic diseases. J Pediatr 1992;121(1):1-11. PMID 1625065
17: Hall PL, Wittenauer A, Hagar A. Newborn screening for medium chain acyl-CoA dehydrogenase deficiency: performance improvement by monitoring a new ratio. Mol Genet Metab 2014;113(4): 274-7. PMID 25454677
18: Iafolla AK, Thompson RJ, Roe CR. Medium-chain acyl-coenzyme A dehydrogenase deficiency: clinical course in 120 affected children. J Pediatr 1994;124(3):409-15. PMID 8120710
19: Ikeda Y, Keese SM, Fenton WA, Tanaka K. Biosynthesis of four rat liver mitochondrial acyl-CoA dehydrogenases: in vitro synthesis, import into mitochondria and processing of their precursors in a cell-free system and in cultured cells. Arch Biochem Biophys 1987;252(2):662-74. PMID 3813556
20: Iverson R, Taljaard M, Geraghty MT, et al. Assessing the quality and value of metabolic chart data for capturing core outcomes for pediatric medium-chain acyl-CoA dehydrogenase (MCAD) deficiency. BMC Pediatr 2024;24(1):37. PMID 38216926
21: Jones LL, McDonald DA, Borum PR. Acylcarnitines: role in brain. Prog Lipid Res 2010;49(1):61-75. PMID 19720082
22: Karunanidhi A, Basu S, Zhao XJ, et al. Heptanoic and medium branched-chain fatty acids as anaplerotic treatment for medium chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab 2023;140(3):107689. PMID 37660571
23: Kennedy S, Potter BK, Wilson K, et al. The first three years of screening for medium chain acyl-CoA dehydrogenase deficiency (MCADD) by newborn screening ontario. BMC Pediatr 2010;10:82. PMID 21083904
24: Keppen LD, Randall B. Inborn defects of fatty acid oxidation: a preventable cause of SIDS. S D J Med 1999;52(6):187-8; discussion 188-9. PMID 10388343
25: Kler RS, Jackson S, Bartlett K, et al. Quantitation of acyl-CoA and acylcarnitine esters accumulated during abnormal mitochondrial fatty acid oxidation. J Biol Chem 1991;266(34):22932-8. PMID 1744086
26: Kormanik K, Kang H, Cuebas D, Vockley J, Mohsen AW. Evidence for involvement of medium chain acyl-CoA dehydrogenase in the metabolism of phenylbutyrate. Mol Genet Metab 2012;107(4):684-9. PMID 23141465
27: Krebs-Drouot L, Schalk A, Schaefer E, et al. Recurrent familial case of early childhood sudden death: complex post mortem genetic investigations. Forensic Sci Int Genet 2024;71:103028. PMID 38518711
28: Leal J, Ades AE, Wordsworth S, Dezateux C. Regional differences in the frequency of the c.985A>G ACADM mutation: findings from a meta-regression of genotyping and screening studies. Clin Genet 2014;85(3):253-9. PMID 23574375
29: Li H, Fukuda S, Hasegawa Y, et al. Effect of heat stress and bezafibrate on mitochondrial beta-oxidation: comparison between cultured cells from normal and mitochondrial fatty acid oxidation disorder children using in vitro probe acylcarnitine profiling assay. Brain Dev 2010;32(5):362-70. PMID 19589653
30: Lim SC, Tajika M, Shimura M, et al. Loss of the mitochondrial fatty acid β-oxidation protein medium-chain acyl-coenzyme A dehydrogenase disrupts oxidative phosphorylation protein complex stability and function. Sci Rep 2018;8(1):153. PMID 29317722
31: Lindner M, Hoffmann GF, Matern D. Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting. J Inherit Metab Dis 2010;33(5):521-6. PMID 20373143
32: Maclean K, Rasiah VS, Kirk EP, et al. Pulmonary haemorrhage and cardiac dysfunction in a neonate with medium-chain acyl-CoA dehydrogenase (MCAD) deficiency. Acta Paediatr 2005;94(1):114-6. PMID 15858970
33: Maier EM, Gersting SW, Kemter KF, et al. Protein misfolding is the molecular mechanism underlying MCADD identified in newborn screening. Hum Mol Genet 2009;18(9):1612-23. PMID 19224950
34: McCandless SE, Chandrasekar R, Linard S, Kikano S, Rice L. Sequencing from dried blood spots in infants with "false positive" newborn screen for MCAD deficiency. Mol Genet Metab 2013;108(1): 51-5. PMID 23151387
35: Mutze U, Nennstiel U, Odenwald B, et al. Sudden neonatal death in individuals with medium-chain acyl-coenzyme A dehydrogenase deficiency: limit of newborn screening. Eur J Pediatr 2022;181(6):2415-22. PMID 35294644
36: Nada MA, Chace DH, Sprecher H, Roe CR. Investigation of beta-oxidation intermediates in normal and MCAD-deficient human fibroblasts using tandem mass spectrometry. Biochem Mol Med 1995;54(1):59-66. PMID 7551818
37: Napolitano N, Wiley V, Pitt JJ. Pseudo-glutarylcarnitinaemia in medium-chain acyl-CoA dehydrogenase deficiency detected by tandem mass spectrometry newborn screening. J Inherit Metab Dis 2004;27(4):465-71. PMID 15303003
38: Potter BK, Little J, Chakraborty P, et al. Variability in the clinical management of fatty acid oxidation disorders: results of a survey of Canadian metabolic physicians. J Inherit Metab Dis 2012;35(1):115-23. PMID 21630065
39: Randall M, Rolf C, Gibson SM, Hall PL, Rinaldo P, Davis GJ. Medium-chain Acyl-CoA dehydrogenase deficiency in adulthood: a potential diagnosis in a patient with mental status changes suspected of drug toxicity. J Forensic Sci 2015;60(4):1101-3. PMID 26223762
40: Reis de Assis D, Maria Rde C, Borba Rosa R, et al. Inhibition of energy metabolism in cerebral cortex of young rats by the medium-chain fatty acids accumulating in MCAD deficiency. Brain Res 2004;1030(1):141-51. PMID 15567346
41: Rinaldo P, O'Shea JJ, Coates PM, Hale DE, Stanley CA, Tanaka K. Medium-chain acyl-CoA dehydrogenase deficiency. Diagnosis by stable-isotope dilution measurement of urinary n-hexanoylglycine and 3-phenylpropionylglycine. N Engl J Med 1988;319:1308-13. PMID 3054550
42: Rinaldo P, Raymond K, Al-Odaib A, Bennett MJ. Clinical and biochemical features of fatty acid oxidation disorders. Cur Opin Pediatr 1998;10(6):615-21. PMID 9848022
43: Rinaldo P, Tortorelli S, Matern D. Recent developments and new applications of tandem mass spectrometry in newborn screening. Curr Opin Pediatr 2004;16(4):427-33. PMID 15273505
44: Rinaldo P, Yoon HR, Yu C, Raymond K, Tiozzo C, Giordano G. Sudden and unexpected neonatal death: a protocol for the postmortem diagnosis of fatty acid oxidation disorders. Sem Perinatol 1999;23(2):204-10. PMID 10331471
45: Ruitenbeek W, Poels PJ, Turnbull DM, et al. Rhabdomyolysis and acute encephalopathy in late onset medium chain acyl-CoA dehydrogenase deficiency. J Neurol Neurosurg Psychiatry 1995;58(2):209-14. PMID 7876853
46: Santos L, Patterson A, Moreea SM, Lippiatt CM, Walter J, Henderson M. Acute liver failure in pregnancy associated with maternal MCAD deficiency. J Inherit Metab Dis 2007;30(1):103. PMID 17186412
47: Saudubray JM, Martin D, de Lonlay P, et al. Recognition and management of fatty acid oxidation defects: a series of 107 patients. J Inherit Metab Dis 1999;22(4):488-502. PMID 10407781
48: Schatz UA, Ensenauer R. The clinical manifestation of MCAD deficiency: challenges towards adulthood in the screened population. J Inherit Metab Dis 2010;33(5):513-20. PMID 20532824
49: Smith EH, Thomas C, McHugh D, et al. Allelic diversity in MCAD deficiency: the biochemical classification of 54 variants identified during 5 years of ACADM sequencing. Mol Genet Metab 2010;100(3):241-50. PMID 20434380
50: Spiekerkoetter U, Bastin J, Gillingham M, Morris A, Wijburg F, Wilcken B. Current issues regarding treatment of mitochondrial fatty acid oxidation disorders. J Inherit Metab Dis 2010;33(5):555-61. PMID 20830526
51: Stanley CA. New genetic defects in mitochondrial fatty acid oxidation and carnitine deficiency. Adv Pediatr 1987;34:59-88. PMID 3318304
52: Stanley CA. Carnitine disorders. Adv Pediatr 1995;42:209-42. PMID 8540429
53: Stanley CA, Berry GT, Bennett MJ, Willi SM, Treem WR, Hale DE. Renal handling of carnitine in secondary carnitine deficiency disorders. Pediatr Res 1993;34(1):89-97. PMID 8356025
54: Stanley CA, Hale DE, Coates PM, et al. Medium-chain acyl-CoA dehydrogenase deficiency in children with non-ketotic hypoglycemia and low carnitine levels. Pediatr Res 1983;17(11):877-84. PMID 6646897
55: Stanley CA, Lieu YK, Hsu BY, et al. Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N Engl J Med 1998;338(19):1352-7. PMID 9571255
56: Stewart PM, Walser M. Failure of the normal ureagenic response to amino acids in organic acid-loaded rats. Proposed mechanism for the hyperammonemia of propionic and methylmalonic acidemia. J Clin Invest 1980;66(3):484-92. PMID 7400325
57: Swigonova Z, Mohsen AW, Vockley J. Acyl-CoA dehydrogenases: Dynamic history of protein family evolution. J Mol Evol 2009;69(2):176-93. PMID 19639238
58: Tanaka K, Gregersen N, Ribes A, et al. A survey of the newborn populations in Belgium, Germany, Poland, Czech Republic, Hungary, Bulgaria, Spain, Turkey, and Japan for the G985 variant allele with haplotype analysis at the medium chain acyl-CoA dehydrogenase gene locus: clinical and evolutionary consideration. Pediatr Res 1997;41(2):201-9. PMID 9029639
59: Tanaka K, Kean E, Johnson B. Jamaican vomiting sickness: biochemical investigation of two cases. N Eng J Med 1976;295:461-7. PMID 940578
60: Vockley J. Long-chain fatty acid oxidation disorders and current management strategies. Am J Manag Care 2020;26(7 Suppl):S147-54. PMID 32840329
61: Vockley J, Ensenauer R. Isovaleric acidemia: new aspects of genetic and phenotypic heterogeneity. Am J Med Genet C Semin Med Genet 2006;142C(2):95-103. PMID 16602101
62: Vockley J, Singh RH, Whiteman DA. Diagnosis and management of defects of mitochondrial beta-oxidation. Curr Opin Clin Nutr Metab Care 2002a;5(6):601-9. PMID 12394635
63: Vockley J, Whiteman DA. Defects of mitochondrial beta-oxidation: a growing group of disorders. Neuromuscul Disord 2002b;12(3):235-46. PMID 11801395
64: Waddell L, Wiley V, Carpenter K, et al. Medium-chain acyl-CoA dehydrogenase deficiency: genotype-biochemical phenotype correlations. Mol Genet Metab 2006;87(1):32-9. PMID 16291504
65: Walter JH, Patterson A, Till J, Besley GT, Fleming G, Henderson MJ. Bloodspot acylcarnitine and amino acid analysis in cord blood samples: efficacy and reference data from a large cohort study. J Inherit Metab Dis 2009;32(1):95-101. PMID 19191006
66: Wang SY, Kannan S, Shay D, Segal S, Datta S, Tsen L. Anesthetic considerations for a patient with compound heterozygous medium-chain acyl-CoA dehydrogenase deficiency. Anesth Analg 2002;94(6):1595-7. PMID 12032035
67: Wang Y, Palmfeldt J, Gregersen N, et al. Mitochondrial fatty acid oxidation and the electron transport chain comprise a multifunctional mitochondrial protein complex. J Biol Chem 2019;294(33):12380-91. PMID 31235473
68: Wilcken B. Fatty acid oxidation disorders: outcome and long-term prognosis. J Inherit Metab Dis 2010;33(5):501-6. PMID 20049534
69: Wilcken B, Haas M, Joy P, et al. Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet 2007;369(9555):37-42. PMID 17208640
70: Wilcken B, Hammond J, Silink M. Morbidity and mortality in medium chain acyl coenzyme A dehydrogenase deficiency. Arch Dis Child 1994;70(5):410-2. PMID 8017963
71: Wilcken B, Wiley V, Hammond J, Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 2003;348(23):2304-12. PMID 12788994
72: Wiles JR, Leslie N, Knilans TK, Akinbi H. Prolonged QTc interval in association with medium-chain acyl-coenzyme A dehydrogenase deficiency. Pediatrics 2014;133(6):e1781-6. PMID 24799540

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Jerry Vockley MD PhD

Dr. Vockley of the University of Pittsburgh School of Medicine has no relevant financial relationships to disclose.
See Profile

Editor

Deepa S Rajan MD

Dr. Rajan of UPMC Children's Hospital of Pittsburgh has no relevant financial relationships to disclose.
See Profile

Former Authors

Charles A Stanley MD
Jennifer Friedman MD

Patient Profile

Age range of presentation: 0 months to 05 years
Sex preponderance: male=female
Heredity: autosomal recessive in 100% of cases
Population groups selectively affected: Northern Europeans

Caucasians
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Disorder of lipoprotein metabolism, unspecified: E78.9
ICD-11: Disorders of mitochondrial fatty acid oxidation: 5C52.01
OMIM: Medium-chain acyl-CoA dehydrogenase deficiency: #201450

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Medium-chain acyl-CoA dehydrogenase deficiency

Associated Disorders

Hypoketotic hypoglycemia
Reye syndrome
Secondary carnitine deficiency
Sudden infant death syndrome

Differential Diagnosis

genetic defects in the fatty acid oxidation pathway
plasma membrane carnitine transporter defect
carnitine palmitoyltransferase I deficiency
carnitine and acylcarnitine translocase deficiency
carnitine palmitoyltransferase II deficiency
- very long-chain acyl-CoA dehydrogenase deficiency
- long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency
- short-chain acyl-CoA dehydrogenase deficiency
- HMG synthase deficiency
- HMG lyase deficiency
- electron transfer flavoprotein deficiency
- electron transfer flavoprotein dehydrogenase deficiency
- Reye syndrome
- genetic defects in amino acid oxidation
- glycogen storage disorders
- gluconeogenic defects
- ketotic hypoglycemia of infancy
- hypopituitarism
- isovaleric acidemia
- urea cycle disorder
- hyperinsulinism
- hyperammonemia syndrome
- hypoketotic hypoglycemia
- Jamaican vomiting illness
- sudden infant death syndrome

Also Relevant

Ethylmalonic encephalopathy and SCAD deficiency
Hyperammonemia not caused by liver failure
Long-chain fatty acid oxidation defects
Multiple acyl-CoA dehydrogenase deficiency
Primary carnitine transporter deficiency
- Sudden infant death syndrome

Clinical Categories

Neurogenetic Disorders

Web References

Testing

Mitochondrial Disorders

Medium-chain acyl-CoA dehydrogenase deficiency

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Carnitine palmitoyltransferase II deficiency

Pyruvate carboxylase deficiency

Pelizaeus-Merzbacher disease

Vanishing white matter disease

Wilson disease

Aromatic L-amino acid decarboxylase deficiency

White matter abnormalities in the brain

Hypermethioninemia

This is an article preview.
Start a Free Account
to access the full version.